About H-Immune
H-Immune is a Healthcare company based in Paris (France) founded in 2016, and was acquired by HiFiBiO in October 2018. Developing MAb immunotherapies to treat cancer. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
H-Immune SAS was founded in 2016 as a spin-out from the French Atomic Energy Commission and is headquartered in Paris, France. Operations focus on the immuno-oncology sector within biotechnology, where proprietary In Vitro Immunization (IVI) technology is employed to produce fully human monoclonal antibodies targeting various cancer therapies. Affinity maturation by B lymphocytes is leveraged in this process. A strategic research partnership with Pierre Fabre was established in March 2017.
- Headquarters Paris, France
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website h-immune.com
- Acquired by HiFiBiO (Oct 2018)
Investors in H-Immune
H-Immune has secured backing from 1 investor. Prominent investors backing the company include HiFiBiO.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Antibody-based drugs are discovered using a specialized technology platform. | 2013 | hifibio.com | Paris, France |
Investor details for H-Immune
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of H-Immune
2 dated milestones of H-Immune across 2 years, from founding to its latest funding, stage changes and deals.
- Founded H-Immune is founded.
- Exit Acquired by HiFiBiO.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about H-Immune
H-Immune was founded in 2016.
H-Immune is headquartered in Paris, France.
H-Immune SAS was founded in 2016 as a spin-out from the French Atomic Energy Commission and is headquartered in Paris, France. Operations focus on the immuno-oncology sector within biotechnology, where proprietary In Vitro Immunization (IVI) technology is employed to produce fully human monoclonal antibodies targeting various cancer therapies. Affinity maturation by B lymphocytes is leveraged in this process. A strategic research partnership with Pierre Fabre was established in March 2017.
H-Immune has 1 investor. Key investors include HiFiBiO.
Yes. H-Immune was acquired by HiFiBiO in October 2018.